Table 3 Demographics and comorbidities of the cases and controls
From: IL-6 and cfDNA monitoring throughout COVID-19 hospitalization are accurate markers of its outcomes
Patients N = 93 | Controls N = 55 | p | ||
|---|---|---|---|---|
Sex | Female | 51 (54.84%) | 30 (54.55%) | 1.000 |
Male | 42 (45.27%) | 25 (45.45%) | ||
Age (years) | 69.00 [55.00; 78.00] | 71.00 [57.00; 79.00] | 0.441 | |
Hypertension | 45 (48.39%) | 17 (30.91%) | 0.056 | |
Diabetes | 28 (30.11%) | 12 (21.82%) | 0.365 | |
Obesity | 13 (13.98%) | 4 (7.27%) | 0.332 | |
Heart disease | 14 (15.05%) | 6 (10.91%) | 0.643 | |
Chronic respiratory disease | 16 (17.20%) | 3 (5.45%) | 0.070 | |
Liver disease | 3 (3.23%) | 0 (0.00%) | 0.295 | |
Renal disease | 8 (8.60%) | 6 (10.91%) | 0.863 | |
Dementia | 18 (19.35%) | 4 (7.27%) | 0.079 | |
Dyslipidemia | 17 (18.28%) | 17 (30.91%) | 0.118 | |